Newsletter
Cipla has joined hands with Bangalore-based Kemwell Biopharma to enter the fast-growing biologics and biosimilars space. The two signed a JV agreement, with Cipla holding a 60% stake and Kemwell owning 40%.
The deets: the partners will set up a new India-based joint venture and initially invest up to ₹10 crore, in line with their shareholding.
The JV will develop, manufacture and sell biologic drugs for global markets, while also handling regulatory approvals and export-import operations.
Quick context: Biologics are advanced medicines made from living cells and are among the fastest-growing segments in pharma.
Kemwell already runs a USFDA-certified facility in Bengaluru with large bioreactors and sterile fill-finish lines, giving the JV ready manufacturing muscle.
Why it matters: Cipla is clearly looking beyond traditional generics. Biologics offer higher margins, global demand and longer product lifecycles.
By partnering with an experienced CDMO like Kemwell, Cipla fast-tracks its entry instead of building everything from scratch.
